Is Camp Lejeune Worth Advertising in 2026? An Acquisition Breakdown

Camp Lejeune case acquisition remains an active strategic decision for plaintiff firms in 2026, even as the litigation enters a later, more complex phase. The administrative claims window has closed, bellwether trials are proceeding in the Eastern District of North Carolina, and DOJ settlement activity through the Elective Option program continues at a measured pace. For firms evaluating whether to commit marketing budget, the core questions are whether a sufficient addressable claimant pool remains, what acquisition costs today, and whether the case economics still pencil out.

The Litigation Landscape and What It Means for Timing

The Camp Lejeune Justice Act, passed as part of the PACT Act in August 2022, created a special administrative claims process against the U.S. government. More than 200,000 claims have been filed in the Eastern District of North Carolina. The DOJ is the effective defendant, and every claim requires individual negotiation or litigation rather than a traditional MDL class resolution. That structure slows everything down.

The government introduced an Elective Option settlement framework organized by injury tier. Tier 1 conditions, including leukemia, kidney cancer, bladder cancer, Non-Hodgkin lymphoma, and Parkinson's disease, are the strongest causation tiers. The VA already concedes causation for eight specific conditions, and IARC classifies the primary contaminants, TCE and PCE, as Group 1 human carcinogens. That scientific foundation is solid. The problem is settlement pace. DOJ has been slow to extend meaningful offers, and the Elective Option values being floated are lower than what firms expect from trial outcomes.

Bellwether trials are expected to run through 2025. Those first verdicts will set the per-condition value benchmarks the whole inventory gets calibrated against. Firms holding strong Tier 1 cases have good reason to wait rather than accept early administrative settlements. For firms considering advertising now, the key question is whether new signed cases can still be acquired at economics that make sense given the timeline to resolution. The honest answer is: yes, but selectively.

Claimant Pool and Demand: Is There Still Volume to Capture?

The exposure window runs from 1953 to 1987. Anyone who lived or worked at Camp Lejeune for 30 or more days during that period, including service members, civilian employees, and family members on base, was potentially exposed. That is a geographically diffuse population. Camp Lejeune is in Onslow County, North Carolina, but the Marines stationed there came from every state in the country, and many have retired or relocated decades ago. That diffusion actually helps on the advertising side: national media buys reach this population reasonably well.

The filing deadline for new administrative claims has passed. That is a meaningful constraint. Any claimant who has not filed cannot start a new administrative track. However, civil suit pathways remain open for claimants whose administrative claims were already filed but not resolved. With more than 200,000 claims in the system and DOJ processing at a bureaucratic pace, a large number of those claimants are still unrepresented or underrepresented. That is the pool firms are competing for: people who filed an administrative claim themselves or through a non-legal service, who have a qualifying diagnosis, and who have not yet signed with a firm.

Saturation is high relative to 2022 and 2023, when advertising volume was at its peak. But high saturation does not mean zero opportunity. It means the economics have shifted. Cost per lead and cost per signed case are up from the early rush, and firms need sharper intake to separate high-tier cases from low-value claimants. Firms willing to qualify aggressively and focus on Tier 1 diagnoses can still build a meaningful inventory.

Camp Lejeune Case Acquisition Economics: The Real Numbers

At peak advertising volume in 2022 and early 2023, cost per signed Camp Lejeune case ranged from roughly $800 to $1,500 for firms running tight intake. By mid-2023 and into 2024, as competition intensified and the lower-tier claimants became harder to qualify, signed-case costs climbed. Today, firms running well-optimized campaigns should expect to pay somewhere in the $1,500 to $3,000 range per signed, qualified Tier 1 case, depending on channel mix, intake quality, and how strictly the firm defines a "qualified" retainer. Firms running loose intake and then disqualifying a large percentage of signed cases skew their effective cost per usable case much higher.

Facebook and Meta-based social advertising has been the dominant channel throughout this tort. The demographic, veterans and their families aged 55 and older, responds well to Facebook and Instagram placements. Google search works for direct-intent traffic but costs more per click and tends to serve a narrower slice of the population. YouTube has performed well for some firms using longer-format educational creative. Programmatic display and connected TV are useful for reach and frequency against a retargeted audience but rarely drive direct conversions at scale on their own.

Creative that converts in this tort leads with the specific contamination history and qualifying conditions rather than broad emotional appeals. Claimants who self-identify based on accurate exposure and diagnosis criteria convert at higher rates and qualify through intake at higher rates. Vague creative produces volume with poor qualification. Specificity is more efficient even when it narrows the top of the funnel.

At MTAA, we price on a transparent cost-plus model: actual ad spend plus a 15% management fee. No hidden markups, no inflated CPL pricing. Across more than $250 million in managed Facebook ad spend for over 600 plaintiff firms in 100-plus torts, Camp Lejeune has been one of the highest-volume torts we have run. We know where the spend works and where it leaks.

Intake and Qualification: How the Firm's Side Needs to Work

Intake is where most firms lose money on Camp Lejeune. The claimant pool is large, but a meaningful percentage of inbound leads either do not have a qualifying diagnosis, cannot confirm the 30-day minimum exposure period, or have already signed with another firm. Running a disciplined intake process from the first contact is not optional, it is the difference between a profitable inventory and an expensive one.

The qualification checklist at intake needs to confirm three things in order: exposure at Camp Lejeune for 30 or more days between August 1953 and December 1987, a diagnosed qualifying condition (Tier 1 diagnoses should be prioritized), and confirmation that an administrative claim was filed before the deadline. For civil suit purposes, the administrative claim filing date matters. Firms should have documentation requirements built into the retainer flow so that medical records and military service records are requested at signing, not months later.

Speed to contact remains critical. Leads that are not contacted within the first few minutes of form submission convert at dramatically lower rates. For firms not staffed for 24/7 intake, AI-assisted intake tools can handle initial outreach, gather preliminary qualifying information, and schedule callbacks without losing the lead to a competitor. This is one of the clearest practical applications of AI for plaintiff firm operations right now. The technology has matured to the point where an AI intake assistant can conduct a credible qualification conversation and hand off a warm, documented lead to a human intake specialist. If your firm is running any significant lead volume and has not looked at this capability seriously, it is worth the evaluation.

How MTAA Runs Camp Lejeune Campaigns

We have run Camp Lejeune advertising for firms of every size, from regional practices building a focused inventory to national referral operations running volume at scale. The campaign structure we use emphasizes Tier 1 diagnosis targeting in creative and landing page copy, which filters the audience before intake even starts. That reduces intake cost and improves qualification rates.

We manage the full campaign: creative development, audience build, media buying, optimization, and reporting. Everything runs on actual ad spend with our 15% fee on top. Firms see exactly what they are spending and exactly what it is producing. For firms that want to layer in AI-assisted intake on top of the media, we can advise on integration with the intake tools that have performed well for our clients.

Given where bellwether timing sits and the processing backlog at DOJ, firms that build their Camp Lejeune inventory in the next 12 months will likely be well-positioned when the first trial verdicts clarify settlement values and negotiations accelerate. The window to acquire at current costs will not stay open indefinitely once verdicts start driving settlement pressure.

Closing: Is Camp Lejeune Case Acquisition Still Worth It?

For firms with the intake infrastructure to qualify aggressively and the financial runway to hold cases through bellwether resolution, Camp Lejeune case acquisition still makes sense. The scientific and legal foundation is strong, the Tier 1 conditions carry real value, and the unrepresented claimant pool, though smaller than two years ago, is not exhausted. The economics require discipline: sharper targeting, faster intake, and tighter qualification standards than the early days of this tort demanded. Firms that run it that way can still build a valuable inventory. Firms that treat it like the wide-open opportunity of 2022 will overpay and underperform. If you want a straight assessment of what a Camp Lejeune case acquisition campaign looks like for your firm's budget and goals, that is exactly the conversation MTAA is built for.